Regulatory Progress — Federal Rescheduling Milestone
DOJ moved FDA‑approved medical cannabis products from Schedule I to Schedule III in April 2026, a constructive industry milestone that management views as a positive tailwind over time (no immediate material impact expected on operations).
Strategic Delisting from Nasdaq Provides Flexibility
Company voluntarily delisted from Nasdaq to gain flexibility to invest across the cannabis ecosystem and expand technology and services previously restricted by exchange policies — management calls this a strategic 'unlock' to pursue growth opportunities.
Revenue in Line with Expectations; Sequential Growth
First quarter revenue was $43.6 million, down 2% year‑over‑year but up 1% sequentially, and described as 'in line' with company expectations; sequential growth driven by increased client spend in March ahead of 4/20.
Profitability and Adjusted EBITDA
Reported net income of $1.7 million for the quarter and adjusted EBITDA of $5.9 million (excluding nonrecurring items), demonstrating positive operating profitability in a constrained environment.
Average Revenue per Paying Client Improved
Average monthly revenue per paying client was $2,914 in the quarter, a marginal increase year‑over‑year; management notes the increase was partly due to churn of lower‑spend clients improving mix.
Liquidity Position and Balance Sheet
Ended the quarter with $57 million of cash and investments (cash, short‑term treasuries and bonds) and highlighted the ability to 'put the balance sheet to work' for strategic investments and platform expansion.